INAB

IN8BIO is a pre-revenue, clinical-stage gamma-delta T cell company that has generated no product sales in any of the last five fiscal years and carries a $141M accumulated deficit. The one genuinely attractive fact here is the balance sheet: $27.3M cash (up 139.9%), only $4.72M total liabilities (down 26.9%), $27.6M equity, and a liabilities/equity ratio of just 0.17x. Losses are narrowing — net loss improved 36.1% to -$19.4M and operating cash burn was -$12.7M — implying roughly two years of runway before another raise. This is a company that has retrenched, not scaled: R&D fell 39.8% to $10.2M after management suspended INB-400 enrollment (Sept 2024) 'to conserve capital.'

On valuation, the striking feature is that the stock trades below net cash. At $1.42 on 9.77M shares, the market cap is ~$13.9M against $27.3M of cash (~$2.79/share) — the market is assigning the pipeline negative value, expecting the burn to destroy the cash pile. That is a real (if grim) margin of safety, but two flags temper it: diluted EPS of -$4.44 on a $19.4M loss over ~9.77M shares only reconciles if the weighted share count was far lower earlier in the year — consistent with a reverse split — and shares outstanding grew 304.2% YoY. Both are hallmarks of a distressed micro-cap managing Nasdaq listing compliance and funding itself through heavy dilution. The below-cash discount is therefore as much a distress signal as a value signal.